Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AL-39324 ophthalmic suspension
AL-39324 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-39324 Concentration Level A | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level B | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level C | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level D | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level E | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| Lucentis | ACTIVE_COMPARATOR | Ranibizumab 10 mg/mL solution, single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AL-39324 ophthalmic suspension | DRUG | - |
| Ranibizumab 10 mg/mL | DRUG | - |
Inclusion Criteria: * Willing to give written informed consent, make the required study visits and follow instructions; * The study eye: * must have a primary diagnosis of choroidal neovascularization (CNV) secondary to AMD; * lesion must be no larger than 30 mm2; * must have edema measuring...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
AL-39324 is an investigational small molecule developed by Alcon Inc. (ticker: ALC) for the treatment of age-related macular degeneration (AMD). It is formulated as an ophthalmic suspension and has been studied in a Phase 2 clinical trial. AL-39324 is not approved for any indication and remains in clinical development.
AL-39324 is being developed for the treatment of age-related macular degeneration (AMD), a leading cause of vision loss. It is intended for patients with the wet form of AMD, as studied in the WALTZ trial. The drug is investigational and has not been approved for any use.
AL-39324 is developed by Alcon Inc., which trades under the ticker symbol ALC. Alcon is an eye care company focused on ophthalmic products. The company is responsible for the clinical development of AL-39324.
AL-39324 is in Phase 2 clinical development. A single Phase 2 trial has been completed. The drug is investigational and has not been approved by the FDA or any regulatory agency for any indication.
AL-39324 has been studied in one completed Phase 2 clinical trial, NCT00992563, also known as the WALTZ trial. The trial enrolled 35 participants with age-related macular degeneration and was randomized, double-blind, and active-controlled. No active trials of AL-39324 are currently listed.
Yes, AL-39324 ophthalmic suspension is another name for AL-39324. The ophthalmic suspension refers to the formulation of the small molecule developed by Alcon Inc. for age-related macular degeneration. Both names refer to the same investigational drug.